Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
AUTOR(ES)
Gomes, Luis Eduardo Miani
FONTE
Clinics
DATA DE PUBLICAÇÃO
26/09/2019
RESUMO
Documentos Relacionados
- Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
- Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
- “Polypill” to fight cardiovascular disease: Authors' reply
- Infliximab-induced remission improves physical activity in patients with active Crohn's disease
- Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease